ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that has shown success in aiding the healing of diabetic wounds and therefore preventing amputations.
Diabetes is a serious medical condition that affects how the body uses blood sugar. Because glucose is vital for your cells to have enough energy, too much of it can lead to major medical problems such as amputations. In 2010, roughly 8% of the American population had diabetes, or 25.8 million people. Of those 25.8 million diagnosed diabetics, 73,000 adults had non-traumatic lower-limb amputations, according to the American Diabetes Association.
TetraStem has shown success in laboratory trials and found to be 99 percent effective against all bacteria. ViaDerma believes the application of TetraStem can maximize the healing of diabetic wounds before they require amputation.
"TetraStem kills infection because of the proprietary, transdermal delivery that allows TetraStem to kill bacteria chemically and physically," says CEO of ViaDerma, Dr. Christopher Otiko. "We hope that the application of TetraStem can help reduce the number of amputations from diabetic wounds, thereby saving lives and increasing people's quality of life."